Want to see HRMY full AI Analyst Report?
HRMY Stock Chart & Stats
$29.99
-$1.07(-3.04%)
At close: 4:00 PM EST
$29.99
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume87.33K
Average Volume (3M)820.23K
Market Cap
$2.21B
Enterprise Value$1.57B
Total Cash (Recent Filing)$640.92M
Total Debt (Recent Filing)$206.51M
Price to Earnings (P/E)14.5
Beta1.01
Next Earnings
Aug 11, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.52
Shares Outstanding57,892,677
10 Day Avg. Volume826,091
30 Day Avg. Volume820,228
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda6.74
Forecast
1Y Price Target
$47.57Price Target Upside58.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)3.46
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a cash-rich position provide durable financial flexibility. This balance sheet lets management fund commercial expansion, business development, and litigation defense without near-term refinancing risk, supporting multi-year execution of strategic priorities.
High Gross Margins & ProfitabilitySustained gross margins in the high-70s give the company structural earnings power and pricing leverage. Even with some margin compression, elevated margins underpin durable cash generation and allow reinvestment in sales, R&D, and targeted BD over the next several quarters.
Commercial Franchise, Pipeline & IP ProtectionEstablished WAKIX sales growth and low market penetration indicate a multi-year commercial runway. Layered IP (ANDA settlements, amorphous patents, utility filings) plus advancing pipeline programs create durable barriers and multiple potential revenue streams beyond the core product.
Bears Say
Rising Cost Of Goods SoldA multi-percentage-point increase in COGS driven by licensing/royalty costs materially reduces gross margin room. If higher royalty burdens persist, the company's long-term margin profile and cash conversion could be structurally lower versus prior years, pressuring reinvestment.
Elevated Operating Expenses & License FeesA substantial near-term increase in operating spend, including a non-recurring $32M license payment, compresses GAAP earnings and muted quarterly cash flow. If BD, commercialization, and trial spending remain elevated, FCF growth could stay constrained over the medium term.
Litigation & Market-Access UncertaintyMulti-year litigation timelines and adjudication risk create durable uncertainty around generic entry and exclusivity. Concurrent payer/plan access headwinds can persistently delay patient starts and adoption, making revenue trajectory and forecast reliability more vulnerable over coming quarters.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $2.21B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on May 07, 2026. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.695 by -$0.145.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.88.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,892,677 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.55 in its last earnings report, missing expectations of $0.695. Following the earnings report the stock price went down -4.149%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.57 (58.62% Upside)
$47.57 (58.62% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 142.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.43%
12-Months-Change
Fundamentals
Return on Equity
17.19%
Trailing 12-Months
Asset Growth
20.49%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
HRMY Company Deck
HRMY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company with strong commercial momentum (17% revenue growth, reaffirmed $1.0–1.04B guidance), a well-funded balance sheet ($870.5M cash), advancing pipeline programs with near-term milestones (BP-205, pitolisant GR/HD, EPX-100), and an assertive IP defense strategy. Offsetting these positives were higher COGS and a sizable increase in operating expenses driven largely by a $32M upfront license fee, a decline in GAAP net income, muted cash flow for the quarter, ongoing litigation with timing/appeal uncertainty, and Q1 market access headwinds. On balance, highlights—particularly revenue traction, cash runway, and pipeline progress—outweigh the lowlights but the company faces near-term cost, legal and access execution risks.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$47.57
▲(58.62% Upside)
Technical Analysis
Ownership Overview
1.11% Insiders
20.89% Mutual Funds
0.33% Other Institutional Investors
47.89% Public Companies and
Individual Investors